Bipartisan Policy Center issues report on IT safety plan

The Bipartisan Policy Center has issued recommendations for the Department of Health and Human Services' proposed health IT safety plan. The Office of the National Coordinator for Health Information Technology released a proposed plan for comment in December 2012. Goals included making it easier to report safety events and risks using EHR reporting tools, developing a code of conduct for IT vendors and incorporating safety in post-market surveillance of certified EHRs.

Four former Senate Majority Leaders--Howard Baker (R), Bob Dole (R), Tom Daschle (D) and George Mitchell (D)--formed the Bipartisan Policy Center in 2007 to facilitate political consensus on national policy in several issue areas, including healthcare. The group issued their recommendations for the IT safety plan in a new report that calls for a safety oversight framework based on the following five principles:

* Recognize and support IT’s important role in improving quality, safety, efficiencies and the patient experience;

* Assure that safety and positive outcomes are shared responsibilities throughout the healthcare system;

* Make a framework that is risk-based, flexible and will not stifle innovation;

* Leverage existing safety and quality-related processes, systems and standards; and

* Establish a non-punitive environment to encouraging reporting of safety issues, learning and improving.

The report, An Oversight Framework for Assuring Patient Safety in Health Information Technology, is available here.

 

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.